MP
VYNT

Manifold Partners’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Manifold Partners’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7
Closed -$21K – 147
2013
Q3 		$21K Buy
+7
New +$12K 0.01% 102

Other funds holding VYNT

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sterneck Capital Management Kansas City, Missouri $233M AUM 21.98% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.72B AUM 7.09% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $2.68B AUM 34.39% 1-Year Est. Return

Manifold Partners's VYNT Position: Q4 2013 in Review

Manifold Partners sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2013, closing a stake of 7 shares — an estimated $21K sold.

Manifold Partners first reported a position in VYNT in Q3 2013 and held it in 1 quarter. The position peaked at $21K in Q3 2013. 29 funds tracked by Wall St. Rank hold VYNT as of Q4 2013.

  • Manifold Partners reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Manifold Partners sold 7 Vyant Bio, Inc. Common Stock shares in Q4 2013, an estimated $21K.
  • Manifold Partners first reported a position in Vyant Bio, Inc. Common Stock in Q3 2013 and held it in 1 quarter.
  • Manifold Partners's Vyant Bio, Inc. Common Stock position peaked at $21K in Q3 2013.
  • 29 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2013.

Based on Manifold Partners's 13F filing for Q4 2013, filed 27 Jan 2014.